Document is current
Any future updates will be listed below
-
Authors
Schwarting, Stéphanie K. https://orcid.org/0000-0001-5954-5695
Poledniczek, Michael
Metodiev, Yuliyan
Stolz, Lukas
Hofmann, Eva
Hegenbart, Ute
Schönland, Stefan
Kääb, Stefan
Massberg, Steffen
Frey, Norbert
aus dem Siepen, Fabian
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 4 November 2024
First Online: 20 November 2024
Declarations
:
: The authors have no competing interests to declare that are relevant to the content of this article. Independently, S.K. Schwarting received speaker honoraria from Pfizer and Alnylam. F. aus dem Siepen received speaker honoraria from and served as consultant for Pfizer. L. Stolz received speaker honoraria from Edwards Lifesciences. U. Hegenbart received speaker honoraria from Janssen, Pfizer, Alnylam, Akcea, Prothena, AstraZeneca and served as consultant for Pfizer, Prothena, Janssen, Alexion and Alnylam. S. Schönland receives research support from Janssen, Prothena and Sanofi, has research cooperations with Neurimmune and Protego, is part of advisory boards for Janssen, Telix and Prothena. S. Schönland additionally received speaker honoraria from AstraZeneca, Sobi, Janssen, Takeda, Pfizer and Prothena. All fees have been transferred to the institution, University Hospital Heidelberg. S. Schönland received travel and congress participation grants from Janssen, Prothena, Celgene, Binding Site and Jazz. S. Kääb received speaker honoraria from Pfizer and Bristol-Meyrs Squibb. N. Frey received lecture fees from AstraZeneca, BoehringerIngelheim, Bayer, Novartis and Pfizer Inc.
